Results 101 to 110 of about 28,367 (198)

EVALUATION OF THE EFFECTIVENESS OF IMPLEMENTING BEDAQUILINE-BASED ORAL REGIMENS FOR THE TREATMENT OF RIFAMPICIN-RESISTANT TUBERCULOSIS IN THE STATE OF SÃO PAULO

Brazilian Journal of Infectious Diseases
Tuberculosis remains the infectious disease with the highest morbidity and mortality worldwide, despite the numerous advances achieved throughout its history with humankind.
Jorge Luiz de Barros Torresi, Ana Angélica Bulção Portela Lindoso   +1 more
doaj   +1 more source

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

, 2014
Objectives: Bedaquiline is the first drug of a new class approved for the treatment of TB in decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 metabolite.
Karlsson, Mats O.,, Kelly E. Dooley, Murray, Stephen, Elin M. Svensson, Mats O. Karlsson, Svensson, Elin M.,, Dooley, Kelly E., Stephen Murray   +7 more
core   +1 more source

Bedaquiline and tuberculosis workshop 30 June 2023 full transcript 09oct2023

Transcript of webinar held on 30th June 2023 "Bedaquiline and Tuberculosis (TB): What might the future hold?" (https://www.ucl.ac.uk/tb/bedaquiline-and-tb-what-might-future-hold; https://www.youtube.com/watch?v=vQJolt6ebkc). There has been minor editing,
Neil Stoker (10247273)
core   +1 more source

FDA Approves New Tuberculosis Drug: Bedaquiline (Sirturo®)

, 2019
Tuberculosis (TB), caused by the acid-fast bacilli (AFB) Mycobacterium tuberculosis, is an infectious disease that continues to greatly impact morbidity and mortality worldwide; in 2011 it caused 1.4 million deaths.
Ruffner, Megan, Hay, Charles, Crawford, Zachary, Wilin, Kent, Roecker, Andrew   +4 more
core  

A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis. [PDF]

Int J Mol Sci
Ushtanit A, Peretokina I, Krylova L, Safonova S, Filippov A, Zimenkov D.   +5 more
europepmc   +1 more source

Breaking barriers in extensively drug-resistant TB: pretomanid-centred long regimen achieves cure in a bedaquiline-resistant strain. [PDF]

IJTLD Open
Schiuma M, Piubello A, Saluzzo F, Cattaneo D, Salari F, Covizzi A, Rizzo A, Fama F, Ciubotariu C, Lombardi A, Antinori S, Riva A, Cirillo DM, Gori A, Torre A.   +14 more
europepmc   +1 more source

Bedaquiline reloading strategies following interruptions during daily dosing. [PDF]

Antimicrob Agents Chemother
Kikstra N, Beek SWv, Maartens G, Brust JCM, Svensson EM, Koele SE.   +5 more
europepmc   +1 more source

Cost-effectiveness evaluation of bedaquiline- and delamanid-containing regimens for multidrug-/rifampicin-resistant tuberculosis in China: a retrospective study based on three nationwide, real-world multicenter cohorts. [PDF]

J Thorac Dis
Sun D, Li Z, Qiu Y, Shu W, Zhang L, Gao J, Liu Y.   +6 more
europepmc   +1 more source

Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. [PDF]

Antimicrob Agents Chemother
Cummings JE, Woolhiser LK, Guglielmi V, Romano A, Pauly S, Zimmerman M, Kaya F, Walter ND, Robertson GT, Slayden RA.   +9 more
europepmc   +1 more source

Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report. [PDF]

Front Pharmacol
Calamelli M, Davoli C, Gerami R, Gulletta M, Lovatti S, Pavesi A, Rossi B, Matteelli A.   +7 more
europepmc   +1 more source